Detection of VipAlbumin® Effect in CD34 and SDF-1 Mobilization in Streptozotocin-induced Diabetes Mellitus Mice

Andi Rizki Adi Pradana¹, Muhammad Sasmito Djiati², Muhaimin Rifa'i²*

¹Master Program of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia
²Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia

Abstract

Diabetes mellitus is a disease in which the body loses its ability to provide tight regulation and maintain a dynamic interaction between the tissue sensitivity and insulin secretion by β cells. The impact of this dysfunctional mechanism is uncontrolled blood glucose levels that lead to hyperglycemia condition. Highly reactive free radicals have a strong interaction between the tissue sensitivity and insulin secretion by β cells. The purpose of this study was to determine the role of VipAlbumin®, a supplement derived from Channa striatus albumin extracts in inhibiting the action of free radicals that are formed due to hyperglycemia condition, which can affect the increase in endothelial progenitor cells relative amount. This study used BALB/C mice that induced to undergo diabetes mellitus through streptozotocin injection intraperitoneally at 5-day old. Mice who have reached 4 week old and positive to diabetes mellitus (blood glucose levels > 200 mg.dl⁻1) will be administered with VipAlbumin® orally for 14 days. VipAlbumin® dosage was divided into 4 groups: positive control (without VipAlbumin®); 1st dose (0.01664 mg. gr⁻¹ BW); 2nd dose (0.416 mg. gr⁻¹ BW); 3rd dose (10.4 mg. gr⁻¹ BW). The last step was flow cytometric analysis to determine the development of endothelial progenitor cells relative amount, which isolated from bone marrow. The variables measured in this study were the relative amount of CD34⁺ and SDF-1. Based to flow cytometric analysis, mice with VipAlbumin® administration did not show any significant improvement in CD34 relative amount when compared to the positive control. Relative amount of Chemokine SDF-1 itself, although only occur at the 3rd dose of VipAlbumin® treatment, has increased and significantly different from the positive control.

Keywords: CD34, diabetes mellitus, free radicals, hyperglycemia, SDF-1, streptozotocin, VipAlbumin®

INTRODUCTION

CD34 is a transmembrane glycoprotein sized 115-kD which is strongly expressed on progenitor/hematopoietic stem cell (HSPC), and progressively decreased when HSPCs differentiate [1,2]. CD34 is a wide used marker to detect hematopoietic progenitor in human. Several researches show that antigen CD34 has signal with transduction capacity and is involved in cell adhesion, which resulting polymerization of actin and homotypic adhesion on cells of CD34⁺ and KG1a [3-7]. Circulation of immature cells derived from bone marrow, one of which is CD34⁺ cells, contributes in holding vascular homeostasis and repair, and play an important role in maintaining vascular endothelial function [8].

The amount of CD34⁺ cells, as the part of endothelial progenitor cells, are lower in diabetic patients compare to those with normal glucose tolerance [9]. This leads to the reinforcement of the disease in triggering the endothelial dysfunction and the other forms of complication.

The high-level of blood glucose and free radicals activity on diabetic patients also can influence the reduction of SDF-1, a chemokine functioned to stimulate the mobilization of endothelial progenitor cells from bone marrow [10]. Stromal cell-derived factor-1 (SDF-1) or CXCL12 is a chemokine for CXC subfamily which is generally characterized as the pre-B cell stimulation factor and clonized from bone marrow cells supernatant [11]. SDF-1 is chemotactic factor for T cells, monocyte, pre-B cell, dendritic, and hematopoietic progenitor cells, and also functioned to support proliferation of B and CD34⁺ progenitor cells. SDF-1 gave its effect by binding with CXCR, a member of G protein-coupled receptor superfamily [14,15].

Responding to ischemia, SDF-1 regulation is usually increased, and through its binding with CXCR4, will stimulate the bone marrow to release EPC (one of them is CD34⁺ cells) which will later
be recruited in ischemic area [10]. In diabetic animal, the deformed response of SDF-1 to ischemia correlates with the decline of progenitor cells release from bone marrow and will cause post-ischemic angiogenesis deformation [16].

To figure out the effect of blood glucose level increase towards cells development which expresses CD34 and SDF-1, mice models of diabetes mellitus are used. The mice are injected by streptozotocin, a molecule of 2-Deoxy-2-[[methyl (nitroso) amino] carbonyl] amino]-β-D glucopyranose, that produce selective toxic toward β cells and inducting diabetes mellitus in most of laboratory animals. High dose of β cells toxin such as streptozotocin and alloxan inducting insulin deficiency and type 1 diabetes with ketosis. But a precise dose calculation would partially destruct β cells mass and conduct mild insulin resistance that characterize type 2 diabetes [17].

The increase of blood sugar level through the injection of streptozotocin would trigger highly reactive radicals formation. In this research, VipAlbumin®, a supplement which extracted from Channa striatus, is used to obstruct free radicals impact on the endothelial progenitor cells activity. Several researches show that the snakehead murrell (Channa striatus) has positive effect as anti-inflammatory agent [18] reviewed from the high arachidonic acids level and important amino acids such as aspartic, glycine, and glutamic acid [19]. It also becomes the key factor in polypeptide formation which takes role in growth and wound healing [20,21]. The other functions are due to substance conductor, osmotic pressure regulator, platelets and anti-thrombotic formation hindrance, increase cells permeability, and as antioxidant [22,23].

**MATERIALS AND METHODS**

This research was conducted from November 2014 to May 2015 in Laboratory of Animal Physiology, Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya.

**Research design**

The research was categorized into experimental research, in which the researcher intentionally manipulating the treatment to see the emerging effect. This research used in vivo procedure. There were 5 different treatment groups, i.e. negative control (healthy mice without streptozotocin injection and VipAlbumin® administration), positive control (diabetes mellitus model mice without VipAlbumin® administration), and diabetes mellitus model mice with VipAlbumin® administration on 3 different doses. Each treatment were divided into 5 repetition.

**In vivo Procedure**

**Diabetes mellitus model-mice induction through streptozotocin injection**

Healthy mice were induced to have diabetes mellitus through streptozotocin injection intra-peritonealy at a dose of 100 mg.kg⁻¹ BW in the age of 5 days. Each mice in this research was assumed to weigh 2.5 g, thus, the proper dose of streptozotocin is 50 µl. This amount derived from the mixture of 0.005 g of streptozotocin powder with 1 ml of citrate buffer. Successfully injected mice were then nurtured in sterile environment. The measurement of blood glucose level was conducted when the mice were reaching 4 weekend, by using glucometer. Mice was diagnosed undergo diabetes mellitus if the blood glucose levels were more than 200 mg.dl⁻¹.

**VipAlbumin® administration on various doses**

Oral administration of VipAlbumin® was done daily for 14 days to the diabetic mice. This administration were divided into 3 treatment doses: 0.01664 mg.g⁻¹ BW (dose 1); 0.416 mg.g⁻¹ BW (dose 2); 10.4 mg.g⁻¹ BW (dose 3). These three doses were derived from the albumin dose conversion for 1 kg of human BW i.e. 33.3 mg.kg⁻¹ with the assumption that the normal weight of adults was 60 kg. In order to figure out VipAlbumin® effect in decreasing blood glucose level, the measurement was done regularly in every 3 days.

**Cell isolation from bone marrow**

Mice were dislocated and dissected. Afterward, the femur and tibia part of the mice were flushed with PBS by using 1 ml spuit at one end. The obtained suspension is later put into propylene tube and centrifuged on 2500 rpm, 10°C temperature, for 5 minutes. The pellet formed was then resuspended with 1 ml PBS. The resuspension then taken 5 µl, put in microtube, and added with 95 µl evans blue. Pipetting is done for homogenization. The amount of successfully isolated cells was later counted with haemocytometer under microscope.
**Antibody staining and Flowcytometric analysis**

The staining process were divided into two phases based on the antibody type used. The first phase was extracellular antibody staining. 250 µl cell suspension isolated from bone marrow was put into microtube and centrifuged on 2500 rpm speed, 10°C temperature, for 5 minutes. Supernatant was eliminated and the pellet was added with 1 µl antibody which has being liquified with 50µl PBS dan 10% FBS. The suspension was later incubated in 4°C ice box for 20 minutes. The staining combination used was FITC-conjugated rat anti-mouse CD34.

The second phase was intracellular antibody staining. After conduct the procedure of extracellular antibody staining, cells were then given with 100 µl fixative solution cytofix/cytoperm and incubated 20 minutes in ice box. Mixed the cells with 500 µl washperm in order to clean the fixative solution remains. The suspension was re-centrifuged on 2500 rpm, 10°C temperature, for 5 minutes, whereas the pellet was then stained with intracellular antibody and incubated for 20 minutes in ice box. The staining combination used is PE/Cy5-conjugated SDF-1. The cells which were incubated by antibody staining is added with 300-500 µl PBS, and then moved into cuvette and being operated in flowcytometry machine.

**Flowcytometric Data Analysis**

The data obtained from flowcytometry then analyzed with BD Cellquest Pro™ software, and continued with the statistical analysis using SPSS version 16 for Windows. The statistical analysis used was one way ANOVA parametric analysis with p = 0,05%, followed by Tukey test.

**RESULT AND DISCUSSION**

**Comparison of blood glucose levels on each treatment**

The comparison of mice blood glucose levels on each treatment was measured regularly once in 3 days, for 15 days (Fig. 1). The positive control group (diabetic mice without VipAlbumin® administration) has significantly higher blood glucose levels than other treatments. Although it is not as high as the positive control, 1st dose (0.01664 mg.g^-1 BW) of VipAlbumin® also has an increase in blood glucose level along with the age. Both 2nd (0.416 mg.g^-1 BW) and 3rd dose (10.4 mg.g^-1 BW) of VipAlbumin® tend to have fluctuated blood glucose levels, which was able to increase or decrease depends on measurement days. However, the blood glucose levels from both treatments were significantly lower than positive control. The negative control has the lowest sugar blood level compared with the other treatments.

**Flow cytometric analysis of CD34^+ relative amount**

We figured out that the relative amount of CD34^+ cells in diabetic mice has a significant decrease compared with the normal mice (Fig. 2). The healing effort through VipAlbumin® administration has not given a notable change yet, whereas none of the three doses of VipAlbumin® treatment can increase CD34 expression and significantly different from the positive control (Fig. 3).
It has been elucidated that diabetic patients experiencing the decrease of circulated progenitor. Although without complication, the amount of progenitor cells majority on diabetic patients still significantly lower than healthy control. The endothelial progenitor cells reduction can also be happened on patients with high blood glucose level and HbA1c (glycated hemoglobin) \[24\]. The previous research mentioned that the amount of CD34+, one type of the immature cell which was circulated in blood and becomes the part of endothelial progenitor cells (EPC), was lower in diabetic
patients compared with subjects having normal tolerance of blood glucose level [9].

The increase of blood glucose level (hyperglycemia) became the main factor to affecting endothelial dysfunction, which was the first criterion of atherosclerosis pathogenesis [25,26]. Endothelial dysfunction takes important role in the development of atherosclerosis, and the circulation of endothelial progenitor cells derived from the bone marrow participating in the repair of vascular endothelial cells and defending the function of endothelial. On the patients with diabetes, it is reported that there was decreasing amount and dysfunction of circulated EPC, contributing to the diabetic microvascular complication [27].

Various research using animal model showed that the circulated EPC cells contribute to re-endothelialization and/or neovascularization therapy [28,29]. Several evidence indicates that various chemokin, cytokine, growth factor and their specific receptors can regulate the mobilization and recruitment of EPC from the bone marrow to the peripherals area, and in the process of proliferation and differentiation [30,31]. The chemokine (motif C-X-C) receptor 4 (CXCR4), receptor for SDF-1, play important role in the mobilization of cells from bone marrow and also in regulating the mobilization and recruitment of EPC [32-36].

One alternative way to prevent complication caused by hyperglycemia condition and the formation of free radicals is through induction of endothelial progenitor cells activation; in which this research using VipAlbumin® administration to conduct that process. Although the result shows that there was no significant increase in relative amount of CD34 compared with the positive control, it does not eliminate the potential function of albumin. Albumin functioned as the antioxidant to obstruct the free radicals ROS/NOS movement, maintaining the extracellular redox equilibrium, and playing role in the transportation process of various molecules such as fatty acid, nitric oxide, hemin, and drugs [37,38]. Some other researches show that in culture condition, albumin can be used as the inhibitor of apoptosis process for macrophages, neutrophil, lymphocyte, and endothelial cells [39-42]. In primary structure form, albumin contains 34 cysteine residues contributing with 17 disulfide bridges to form whole tertiary structure with one free cysteine residue (Cys34) which plays important role in various functions of albumin mentioned before. This very active residue that containing 80% (500 μmol.L⁻¹) total thiol in plasma is the primary scavenger of reactive oxygen and nitrogen in plasma [43].

Another strategy also proposed to improve the healthy condition from diabetic patients with hyperglycemia by using propolis treatment [44]. This material is known to contain high-level of nutrient factor such as vitamins, polyphenols, and amino acids, that expected to improve insulin sensitivity and suppress the action of inflammatory molecules. This suppression activity had a high relationship with the ability of T regulatory cells (especially on CD4⁺CD25⁺ population), while the increase number of this cells can induced by propolis intake. Highly reactive T cells could induce insulin resistance by its pro-inflammatory action, but T regulatory cells can prevent this effect by producing IL-10 and TGF-β. This cells can also prevents inflammatory condition being wide-spread, by reversing the activated memory T cells become naive type [45].

Flow cytometric analysis of SDF-1 relative amount

Flow cytometric data analysis shows that relative amount of SDF-1 on diabetic mice was significantly decrease compared to the normal control (Fig. 4). Two given doses of VipAlbumin® i.e. 1st dose (0.01664 mg.g⁻¹ BW) and 2nd dose (0.416 mg.g⁻¹ BW) did not show meaningful increase of SDF-1 expression. The significant increase compared with the positive control only occurred in the 3rd dose (10.4 mg.g⁻¹ BW) of VipAlbumin®, although the relative amount has not yet reached the normal condition (Fig. 5).

It was reported that diabetic patients will experience the decrease of SDF-1, a chemokine that stimulates the endothelial progenitor cells mobilization (EPC) derived from the bone marrow [10]. The decreased ability of EPC mobilization from the bone marrow becomes one of the mechanism resulting the low amount of circulated EPC [28,36]. It has been known that SDF-1 and the expression of its receptor (CXCR4) play an important role in the regulation of mobilization and recruitment of progenitor cells, so that the reduction of the molecules estimated to be the cause of low amount of circulated EPC [32,34,36]. The cells expressing CXCR4 correlates positively with the progenitor cells amount on normal individual, while on diabetic patients, there is no correlation. Other research indicated that there is significant decrease of CXCR4 expression in PBMC of type 2 diabetic patients [24].
The decrease of circulated EPC amount is affected by the low ability of EPC cells in responding to SDF-1 [36]. It was also reported that on diabetic patients, there is decrease in ability of CD34⁺ cells in migrating, which is affected by the disability in responding the SDF-1 performance [46]. The genotype of SDF-1 can influences insulin in mobilizing mature progenitor cells on type 2 diabetic patients [47].

**CONCLUSION**

In this research, the administration of three doses of VipAlbumin® were not capable to increase CD34 relative amount, one of
endothelial progenitor cells marker derived from bone marrow. 1st and 2nd dose of VipAlbumin® also has no ability to stimulate the development of SDF-1 relative amount. The development of this molecule only occur at the 3rd dose of VipAlbumin® (10.4 mg.g⁻¹ BW), and was significantly different from positive control.

ACKNOWLEDGEMENT
We would like to thank Mr. Mansur Ibrahim for providing fund for this research. We also thank to Dinia Rizqi and Ganis Tri S. for their support during the process of this research, and to Qonitatul K. for the correction of this manuscript.

REFERENCES
[1] Caux, C., C. Favre, S. Saeland, V. Duvert, P. Mannoni, I. Durand. 1989. Sequential loss of CD34 and class II MHC antigens on purified cord blood hematopoietic progenitors cultured with IL-3: characterization of CD34+, HLA-DR+ cells. Blood. 74. 1287-1294.
[2] He, X.Y., V.P. Antao, D. Basila, J.C. Marx, B.R. Davis. 1992. Isolation and molecular characterization of the human CD34 gene. Blood. 79. 2296-2302.
[3] Tada, J., M. Omine, T. Suda, N. Yamaguchi. 1999. A common signaling pathway via syk and lyn tyrosine kinases generated from capping of the sialomucins CD34 and CD43 in immature hematopoietic cells. Blood. 93. 3723-3735.
[4] Majdic, O., J. Stockl, W.F. Pickl, J. Bohuslav, H. Strobl, C. Scheinecker. 1994. Signaling and induction of enhanced cytoadhesiveness via the hematopoietic progenitor cell surface molecule CD34. Blood. 83. 1226-1234.
[5] Gordon, M.Y., S.B. Marley, R.J. Davidson, F.H. Grand, J.L. Lewis, D.X. Nguyen. 2000. Contact-mediated inhibition of human hematopoietic progenitor cell proliferation may be conferred by stem cell antigen, CD34. Hematol. J. 1. 77-86.
[6] Healy, L., G. May, K. Gale, F. Grosveld, M. Greaves, T. Enver. 1995. The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc. Natl. Acad. Sci. USA. 92. 12240-12244.
[7] Bullock, T.E., B. Wen, S.B. Marley, M.Y. Gordon. 2007. Potential of CD34 in the regulation of symmetrical and asymmetrical divisions by hematopoietic progenitor cells. Stem Cells. 25. 844-851.
[8] Majka, M., A. Janowska-Wieczorek, J. Ratajczak. 2001. Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 15. 3075–3085.
[9] Fadini, G.P., E. Boscaro, S. de Kreutzenberg. 2010. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 33. 1097–1102.
[10] Ceradini, D.J., A.R. Kulkarni, M.J. Callaghan, O.M. Tepper, N. Bastidas, M.E. Kleinman, J.M. Capla, R.D. Galiano, J.P. Levine, G.C. Gurtner. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10. 858–864.
[11] Nagasawa, T., H. Kikutani, T. Kishimoto. 1994. Molecular cloning and structure of a pre-b-cell growth-stimulating factor. PNAS. 91. 2305–2309.
[12] Luster, A.D. 1998. Chemokines—chemotactic cytokines that mediate inflammation. New England J. Med. 338. 436–445.
[13] Christopherson, K., R. Hromas. 2001. Chemokine regulation of normal and pathologic immune responses. Stem Cells. 19. 388–396.
[14] Nagasawa, T., S. Hirota, K. Tachibana, N. Takakura, S. Nishikawa, Y. Kitamura, N. Yoshida, H. Kikutani, T. Kishimoto. 1996. Defects of b-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382. 635–638.
[15] Zou, Y.R., A.H. Kottmann, M. Kuroda, I. Taniuchi, D.R. Littman. 1998. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393. 595–599.
[16] Fadini, G.P., S. Sartore, M. Schiavon, M. Albiero, I. Baesso, A. Cabrelle, C. Agostini, A. Avogaro. 2006. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia. 49. 3075–3084.
[17] Portha, B., O. Blondel, P. Serradas, R. McEvoy, M.H. Girox, Kergoat. 1989. The rat models of non-insulin dependant diabetes induced by neonatal streptozotocin. Diabete Metab. 15. 61-75.
[18] Somchit, M.N., M.H. Solihah, D.A. Israf, A. Zuraini, A.K. Arifah, A.M. Mat Jais. 2004. Effects of three local malaysian Channa spp.
fish on chronic inflammation. J. Orient. Pharm. Exp. Med. 5. 91–94.
[19] Zuraini, A., M.N. Somchit, M.H. Solihah, Y.M. Goh, A.K. Arifah, M.S. Zakaria, N. Somchit, M.A. Rajion, Z.A. Zakaria, A.M. Mat Jais. 2006. Fatty acid and amino acid composition of three local malaysian Channa spp. fish. Food Chem. 97. 674–678.
[20] Heimann, W. 1982. Fundamentals of food chemistry. Avi Pub. Co. West Port, CT, USA. 27-233.
[21] Chyun, J.H., P. Griminger. 1984. Improvement of nitrogen retention by arginine and glycine supplementation on its relation to collagen synthesis in traumatized mature and aging rats. J. Nutr. 114. 1705–1715.
[22] Sunatrio, S. 2004. The impact of albumin serum on length of postoperative wound healing process. Faculty of Medical. Gadjah Mada University. Yogyakarta.
[23] Egan, C.G., R. Lavery, F. Caporali, C. Fondelli, F. Laghi-Pasini, F. Dotta, V. Sorrentino. 2008. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia. 51. 1296-1305.
[24] Kawano, H., T. Motoyama, O. Hirashima, N. Hirai, Y. Miyao, T. Sakamoto, K. Kugiyama, H. Ogawa, H. Yasue. 1999. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol. 34. 146–154.
[25] Wascher, T.C., I. Schmoelzer, A. Wiegretz, M. Stuehlinger, D. Mueller-Wieland, J. Kotzka, M. Enderle. 2005. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur. J. Clin. Invest. 35. 551–557.
[26] Fadini, G.P., M. Miorin, M. Facco. 2005. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45. 1449–1457.
[27] Takahashi, T., C. Kalka, H. Masuda. 1999. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5. 434–438.
[28] Isner, J.M., T. Asahara. 1999. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103. 1231–1236.
[29] Asahara, T., T. Murohara, A. Sullivan. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275. 964–967.
[30] Hristov, M., W. Wolfgang, P.C. Weber. 2003. Endothelial progenitor cells—mobilization differentiation and homing. Arterioscler Thromb. Vasc. Biol. 23. 1185–1189.
[31] Kucia, M., J. Ratajczak, M.Z. Ratajczak. 2005. Bone marrow as a source of circulating CXCR+ tissue-committed stem cells. Biol. Cell. 97. 33–146.
[32] Ceradini, D.J., G.C. Gurtner. 2005. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc. Med. 15. 57–63.
[33] de Almodovar, C. R., A. Luttun, P. Carmeliit. 2006. An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell. 124. 18–21.
[34] Yamaguchi, J., K.F. Kusano, O. Masuo. 2003. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 107. 1322–1328.
[35] Walter, D.H., J. Haendeler, J. Reinhold. 2005. Impaired CXCR4 signaling contributes to the reduced neovascularisation capacity of endothelial progenitor cells from patients with coronary artery disease. Circ. Res. 97. 1142–1151.
[36] Quinlan, G.J., G.S. Martin, T.W. Evans. 2005. Albumin: biochemical properties and therapeutic potential. Hepatology. 41. 1211–1219.
[37] Peters, T. 1996. All about albumin: biochemistry, genetics, and medical applications. Academic Press, San Diego, California, USA.
[38] Iglesias, J., V.E. Abernethy, Z. Wang, W. Lieberthal, J.S. Koh, J.S. Levine. 1999. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am. J. Physiol. 277.711–722.
[39] Moran, E.C., A.S. Kamiguti, J.C. Cawley, A.R. Pettitt. 2002. Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia. British J. Haematol. 116. 316–328.
[40] Kouoh, F., B. Gressier, M. Luyckx. 1999. Antioxidant properties of albumin: effect on
oxidative metabolism of human neutrophil granulocytes. *Farmaco*. 54. 695–699.

[42] Bolitho, C., P. Bayl, J.Y. Hou. 2007. The anti-apoptotic activity of albumin for endothelium is mediated by a partially cryptic protein domain and reduced by inhibitors of G-coupled protein and PI-3 kinase, but is independent of radical scavenging or bound lipid. *J. Vasc. Res*. 44. 313–324.

[43] Turell, L., R. Radi, B. Alvarez. 2013. The thiol pool in humanplasma: the central contribution of albumin to redox processes. *Free Radical Biol. Med*. 65. 244–253.

[44] Rifa‘i, M., N. Widodo. 2014. Significance of propolis administration for homeostasis of CD4⁺CD25⁺ immunoregulatory T cells controlling hyperglycemia. *Springer Plus*. 3. 1-8.

[45] Rifa‘i, M. 2013. CD4⁺CD25⁺ regulatory T cells preventing detrimental autoimmune reactions. *Open Autoimm J*. 5. 1-5.

[46] Segal, M.S., R. Shah, A. Afzal. 2006. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. *Diabetes*. 55. 102–109.

[47] Humpert, P.M., R. Neuwirth, M.J. Battista. 2005. SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes. *Diabetes Care*. 28. 934–936.